全文获取类型
收费全文 | 15062篇 |
免费 | 1308篇 |
国内免费 | 379篇 |
专业分类
耳鼻咽喉 | 224篇 |
儿科学 | 270篇 |
妇产科学 | 249篇 |
基础医学 | 1811篇 |
口腔科学 | 286篇 |
临床医学 | 1793篇 |
内科学 | 2622篇 |
皮肤病学 | 237篇 |
神经病学 | 1166篇 |
特种医学 | 404篇 |
外国民族医学 | 4篇 |
外科学 | 1868篇 |
综合类 | 1177篇 |
现状与发展 | 1篇 |
一般理论 | 14篇 |
预防医学 | 1526篇 |
眼科学 | 360篇 |
药学 | 1338篇 |
4篇 | |
中国医学 | 458篇 |
肿瘤学 | 937篇 |
出版年
2023年 | 154篇 |
2022年 | 302篇 |
2021年 | 582篇 |
2020年 | 423篇 |
2019年 | 434篇 |
2018年 | 437篇 |
2017年 | 408篇 |
2016年 | 399篇 |
2015年 | 518篇 |
2014年 | 657篇 |
2013年 | 742篇 |
2012年 | 973篇 |
2011年 | 939篇 |
2010年 | 612篇 |
2009年 | 504篇 |
2008年 | 793篇 |
2007年 | 752篇 |
2006年 | 678篇 |
2005年 | 679篇 |
2004年 | 588篇 |
2003年 | 605篇 |
2002年 | 521篇 |
2001年 | 406篇 |
2000年 | 324篇 |
1999年 | 306篇 |
1998年 | 143篇 |
1997年 | 141篇 |
1996年 | 115篇 |
1995年 | 109篇 |
1994年 | 103篇 |
1993年 | 77篇 |
1992年 | 165篇 |
1991年 | 145篇 |
1990年 | 182篇 |
1989年 | 125篇 |
1988年 | 132篇 |
1987年 | 131篇 |
1986年 | 111篇 |
1985年 | 119篇 |
1984年 | 91篇 |
1983年 | 75篇 |
1982年 | 66篇 |
1979年 | 81篇 |
1978年 | 67篇 |
1975年 | 55篇 |
1974年 | 47篇 |
1973年 | 64篇 |
1972年 | 57篇 |
1971年 | 47篇 |
1969年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
2.
当代社会,老年人口比例呈现不断上升的趋势,老龄化问题日益严峻。因此,如何有效地延缓衰老不仅成为了世界医学研究的热点,也成为了全球亟待解决的问题。中医药在延缓衰老方面经验丰富,而滋阴药在此类研究中效果显著。本文通过整理滋阴药抗衰老作用机制的若干文献,对滋阴复方六味地黄丸、二至丸、左归丸及其他滋阴中药延缓衰老的机制研究进展进行综述。 相似文献
3.
4.
艾灸作为中医学最古老的疗法之一,作用多样,应用广泛,疗效显著。随着科技的发展,人们对灸法的认识逐渐深入,其中艾烟的相关研究也硕果累累,其安全性广受关注。通过对艾烟作用和安全性评价研究中取得的成果进行归纳分析,以期为艾灸临床安全应用提供指导。 相似文献
5.
6.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
7.
C. Jacquet F. Goehringer E. Baux J.A. Conrad M.O. Ganne Devonec J.L. Schmutz G. Mathey H. Tronel T. Moulinet I. Chary-Valckenaere T. May C. Rabaud 《Médecine et maladies infectieuses》2019,49(2):112-120
Objective
The teaching hospital of Nancy, France, implemented a specific multidisciplinary care pathway (French acronym AMDPL) to improve the management of patients presenting with Lyme borreliosis (LB) suspicion. We aimed to assess the first year of activity of this care pathway.Patients and methods
We included all patients managed in the AMDPL pathway from November 1, 2016 to October 31, 2017. The first step was a dedicated Lyme disease consultation with an infectious disease specialist. Following this consultation, the LB diagnosis was either confirmed and adequate treatment was prescribed, or a differential diagnosis was established and patients received adequate management, or further investigations were required and patients were offered multidisciplinary management as part of a day hospitalization.Results
A total of 468 patients were included. LB diagnosis was confirmed in 15% of patients (69/468), 49% of patients received a differential diagnosis, and 26% (122/468) of patients had the LB diagnosis ruled out without receiving any other diagnosis.Conclusions
This is to our knowledge the first multidisciplinary center implemented in France for the management of patients presenting with LB suspicion related to polymorphous signs and symptoms. Several diagnoses could be confirmed or corrected, although some symptoms and complaints could not be explained. This cohort could improve our knowledge of LB and its differential diagnoses. 相似文献8.
9.
Facundo Davaro Jacob Roberts Allison May Coleman McFerrin Sameer Siddiqui Zachary Hamilton 《Journal of robotic surgery》2020,14(3):447-454
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di 相似文献